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Abstract
Introduction: Interleukin-32 (IL-32) is a recently described cytokine that is a strong inducer of pro-inflammatory 
cytokines such as tumor necrosis factor (TNF)-α, IL-1β, IL-6, and IL-8. The expression of this cytokine is highly increased 
in the rheumatoid synovium and correlated with the severity of joint inflammation. Little is known regarding the innate 
immune-related regulation of IL-32 by fibroblast-like synoviocytes (FLSs). We therefore investigated the effect of innate 
immune stimulation by ligands of Toll-like receptor (TLR)2, TLR3, and TLR4, and cytokines such as TNF-α and interferon 
(IFN)-γ, on IL-32 expression by FLSs.
Methods: FLSs were isolated from patients with rheumatoid arthritis (RA) according to the ACR criteria. Quantitative 
RT-PCR, confocal analysis, and ELISA were performed to evaluate IL-32 mRNA induction and IL-32 release by FLSs 
stimulated with TLR2 (BLP), TLR3 (poly I:C), and TLR4 (lipopolysaccharide) ligands, TNF-α and IFN-γ.
Results: TLR2, -3, and -4 ligands as well as IFN-γ and TNF-α induced IL-32 β, γ and δ mRNA expression by RA FLSs. 
Mature IL-32 was expressed intracellularly and released by cells stimulated with the various activators. The IL-32α 
isoform was expressed intracellularly in response to TNF-α and poly I:C and not released in culture supernatants. 
Stimulation of FLS with TNF-α, BLP, lipopolysaccharide, or poly I:C concomitant with IFN-γ increased IL-32 expression 
compared with stimulation with IFN-γ alone.
Conclusions: IL-32 synthesis by FLSs is tightly regulated by innate immunity in rheumatoid arthritis. Thus TNF-α, IFN-γ, 
double-strand RNA, hyaluronic acid, or other damage-associated molecular patterns (DAMPs), highly secreted in 
synovial tissues of RA patients, might trigger IL-32 secretion by FLSs. IL-32 might therefore represent a relevant 
therapeutic target in RA.
Introduction
Rheumatoid arthritis (RA) is a systemic inflammatory
disease that affects predominantly multiple peripheral
joints. Although the exact mechanisms that contribute to
the pathogenesis are still largely unknown, it is well
accepted that numerous inflammatory cells such as T and
B cells, fibroblast-like synoviocytes, antigen-presenting
cells, and their extensive production of proinflammatory
mediators such as TNF-α, IL-1, IL-6, IL-15, IL-17, and IL-
18, are implicated [1].
IL-32, a recently described cytokine produced mainly
by NK cells, T lymphocytes, epithelial cells, and blood
monocytes stimulated by IL-2 or IFN-γ, has recently
emerged as an important player in innate immune
r e s p o n s e s  [ 2 , 3 ] .  T h i s  p r o i n f l a m m a t o r y  c y t o k i n e  i s  a
strong inducer of other proinflammatory cytokines such
as TNF-α, IL-1β, IL-6, IL-8, and macrophage inflamma-
tory protein-2 (MIP-2) [3-5]. More recently, it was shown
that IL-32 increases IFN-γ production by PBMCs [6,7].
IL-32 might play an important role in inflammatory dis-
eases such as inflammatory bowel diseases and RA [8-
10]. IL-32 is highly expressed in RA synovial tissues but
not in OA synovial biopsies. Microarray studies in cul-
tured FLSs obtained from patients with RA have shown
that the IL-32 gene is one of the most prominently
expressed in RA FLSs [11]. Synovial expression of IL-32 is
strongly correlated with that of TNF-α and IL-1β but also
with the severity of joint inflammation.
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Current evidence indicates that FLSs, which constitute
the synovial lining, are key actors in pannus formation
and the subsequent destruction of cartilage and bone in
the joint [12]. Activation of FLSs may be linked either to
the cytokine environment, to cell-to-cell contacts, or to
interactions between pathogen-associated molecular pat-
terns (PAMPs) or damage-associated molecular patterns
(DAMPs) and pattern-recognition receptors (PRRs). Bac-
terial products, such as lipopolysaccharide (LPS) or pep-
tidoglycan, are known to activate FLSs by interacting with
PRRs present on these cells [13,14]. A large number of
PRRs, such as TLR2, TLR4, and TLR3, are expressed by
FLSs, and their expression is increased in response to
inflammatory stimuli [15,16].
FLSs exert a pro-inflammatory activity, essentially by
synthesizing cytokines, chemokines, prostanoids, and
nitric oxide (NO) [12]. Secretion by FLSs of some cytok-
ines, like IL-6, IL-8, and B-cell-activating factor is regu-
lated by TNF-α, IFN-γ, and PAMPS [17,18]. We therefore
investigated the effect of innate immune stimulation by
ligands of TLR2, TLR3, TLR4, and cytokines such as
TNF-α and IFN-γ, on IL-32 expression by FLSs.
Materials and methods
Cell culture
H u m a n  F L S s  w e r e  i s o l a t e d  f r o m  s y n o v i a l  t i s s u e s  f r o m
four different RA and OA (osteoarthritis) patients at the
time of knee-joint arthroscopic synovectomy, as
described previously [19]. The diagnosis conformed to
the revised criteria of the American College of Rheuma-
tology [20]. Normal FLSs were isolated from synovial tis-
sues obtained with arthroscopic biopsy. Informed
consent was provided according to the Declaration of
Helsinki and obtained from all patients. Approval by the
ethical committee of the Hopitaux Universitaires de
Strasbourg was obtained. FLS cultures were made as pre-
viously described [21]. Experiments were performed
between the third and the ninth passages. Cell number
and cell viability were checked by the MTT test, as
described elsewhere [22].
Stimulation of cells
FLSs (106 cells) were stimulated with 2 ml of medium
alone or medium containing IFN-γ (0.1 ng/ml), TNF-α
(10 ng/ml) (R&D Systems, Lille, France), LPS from Sal-
monella abortus equi (Sigma, St. Quentin Fallavier,
France) (1 μg/ml), BLP (EMC Microcollections GMBH,
Tübigen, Germany) (1 μg/ml), and poly I:C (Invivogen,
Toulouse, France) (10 μg/ml). After a 4- or 24-h incuba-
tion period, total RNA was extracted by using TRIzol
according to the manufacturer's instructions. FLS (2 ×
105 cells) were stimulated with 1 ml of complete medium
containing the various activators for 24 h. An IL-32α-
specific ELISA test was obtained from Biolegend (Ozyme,
Saint Quentin en Yveline, France). IL-32 release was mea-
sured with ELISA with the monoclonal antibody KU32-
56 as a capture antibody and the biotinylated monoclonal
antibody KU32-52 as the detection antibody, according to
the manufacturer's instructions (Biolegend, Ozyme, Saint
Quentin en Yveline, France). The IL-6-specific ELISA test
was from R&D Systems.
Real-time quantitative RT-PCR
Total RNA isolated from FLSs was reverse transcribed by
using the First Strand cDNA Synthesis Kit, according to
the manufacturer's instructions (In Vitrogen). Real-time
quantitative RT-PCR was performed in a total volume of
20 μl by using a SensiMix Plus SYBR (Quantace; Corbett
Life Science, Sydney, Australia) and gene-specific prim-
ers:
IL-32: 5'-TGAGGAGCAGCACCCAGAGC-3'
and 5'-CCGTAGGACTGGAAAGAGGA-3'
IL-32α: 5'-CTGAAGGCCCGAATGCACCA-3'
and 5'-CCGTAGGACTTGTCACAAAA-3'
IL-32β: 5'-CTGAAGGCCCGAATGCACCAG-3'
and 5'-GCAAAGGTGGTGTCAGTATC-3'
IL-32γ: 5'-TGACATGAAGAAGCTGAAGGC-3'
and 5'-CATGACCTTGTCACAAAAGCTC-3'
IL-32δ: 5'-TCTCTGATGACATGAAGAAGCT-3'
and 5'-GCAAAGGTGGTGTCAGTATC-3'
GAPDH: 5'-GGTGAAGGTCGGAGTCAACGGA-3'
and 5'-GAGGGATCTCGCTCGCTCCTGGAAGA-3'
IRF-1: 5'-AAAAGGAGCCAGATCCCAAGA-3'
and 5'-CATCCGGTACACTCGCACAG-3'
IRF-3: 5'-AGCAGAGGACCGGAGCAA-3'
and 5'-AGAGGTGTCTGGCTGGGAAA-3'
IL-32 isoforms were reverse transcribed and amplified.
Amplification products were detected as an increased
fluorescent signal of SYBRGreen during the amplification
cycles. Results were obtained by using SDS Software (Per-
kin Elmer) and evaluated by using Excel (Microsoft).
Melting-curve analysis was performed to assess the spec-
ificity of PCR products. Results were normalized to
GAPDH and expressed as the fold change compared with
samples from cells incubated in medium.
Immunostaining and confocal microscopy
FLSs (5 × 104 cells/well; IbiTreat slides) were stimulated
with medium containing the various activators. After a
16-h incubation-period, cells were fixed with paraformal-
dehyde, 4%, at 4°C, washed with PBS, and permeabilized
with 0.2% Triton X100 in PBS, pH 7.4, for 10 min. FLSs
were incubated with goat anti-IL-32 antibodies (Santa
Cruz Biotechnology, Santa Cruz, CA, USA) overnight at
4°C and then with FITC rabbit anti-goat antibodies for 1
h at 25°C. Fluorescence was analyzed with confocal
microscopy.Alsaleh et al. Arthritis Research & Therapy 2010, 12:R135
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Detection of cellular IL-32α
FLSs (2 × 104 cells) were seeded into 96-well plates and
then incubated for 16 h and 24 h in 200 μl of complete
medium containing the different activators. Cells were
then fixed with 4% paraformaldehyde in PBS, pH 7.4, for
20 min. Free aldehyde groups were quenched with
NH4Cl, 50 mM, in PBS, pH 7.4, for 20 min. Nonspecific
binding was blocked by incubation in PBS containing
0.2% bovine serum albumin and 0.05% saponin for 30 min
at 37°C. The cells were then incubated with biotinylated
anti-IL-32α antibodies (Biolegend; Ozyme, Saint Quentin
en Yveline, France) for 2 h. Absorbance was measured at
450 nm.
Transfections
The siRNA duplexes used in our study were designed to
target sequences for human IRF-1  [GenBank:
NM_002198] gene. Four selected siRNA oligonucleotides
consisting of sequences of 21 nucleotides were supplied
by Dharmacon (Perbio Science, France). Transient trans-
fection of FLSs with siRNA (100 nM) was performed by
using the Human Dermal Fibroblast Nucleofactor kit
from Amaxa, as previously described [23]. FLSs were
then plated in 24-well plates (2 × 105 cells per well). All
assays were performed 48 h after transfection. The con-
trol was carried out with the Dharmacon siControl non-
targeting siRNA consisting of a four-oligonucleotide
pool. Transfection efficiency was evaluated with the
PmaxGFP control vector.
Statistical analysis
Values are expressed as mean ± SEM. The significance of
the results was analyzed with Wilcoxon's test. The P val-
ues < 0.05 were considered significant.
Results
Effect of IFN-γ and TNF-α on IL-32 synthesis and release by 
activated RA FLSs
Stimulation of RA FLSs with IFN-γ induced a dose-
dependent production of IL-32 transcripts, which were
detectable within 4 h (Figure 1a). IL-32mRNA expression
was also compared in normal, OA, and RA FLSs activated
with 0.1 ng/ml of IFN-γ. As shown in Figure 1a, amounts
of IL-32 transcripts were higher in stimulated RA FLSs
compared with normal and OA FLSs.
We next investigated the expression of the different iso-
types in RA FLSs. Treatment with IFN-γ at a concentra-
tion of 0.1 ng/ml resulted in an increasing amount of IL-
32β, γ, and δ transcripts, which were detectable within 4
h (Figure 1b), with a mean increase of seven-, three-, and
fivefold after stimulation for 24 h, respectively (Figure
1c). IL-32α mRNA was not expressed at 4 and 24 h (Fig-
ure 1b, c). To determine whether increased IL-32 mRNA
synthesis led to IL-32 protein expression, immunostain-
ing was performed with a polyclonal anti-human IL-32
antibody, which detected all isoforms (α, β, γ, δ). By using
confocal microscopy, no basal expression of IL-32 was
observed in unstimulated FLS (Figure 1d/a). IL-32 was
strongly expressed after a 24-h incubation with IFN-γ
(Figure 1d/c). By using an ELISA test that detected IL-32,
we observed that IFN-γ induced IL-32 release by FLSs at
24 (55 pg/ml ± 18 pg/ml) and 48 h (125 pg/ml ± 30 pg/
ml), compared with nonactivated cells (Figure 1e). The α
isoform of IL-32 (IL-32α) protein was neither detected
intracellularly in IFN-γ-activated FLSs (Figure 1f) nor
released (data not shown).
Stimulation of RA FLSs with TNF-α induced a dose-
dependent production of IL-32 mRNA, which was
detectable within 4 h (Figure 2a). By using normal, OA,
a n d  R A  F L S s  a c t i v a t e d  w i t h  5  n g / m l  o f  T N F - a ,  w e
observed that amounts of IL-32 transcripts were higher
in stimulated RA FLSs compared with normal and OA
FLSs (Figure 2a).
We then assessed the expression of the different iso-
types. After stimulation with TNF-α, IL-32α, β, γ, and δ
mRNA were detectable within 4 h, with a mean increase
of four-, nine-, five- and eightfold after stimulation for 24
h, respectively (Figure 2b, c). Protein expression and
release by TNF-α-activated FLSs was demonstrated by
immunostaining (Figure 2d/c) and by ELISA (Figure 2e).
Mature IL-32α was detected intracellularly (Figure 2f) but
not released (data not shown).
Effect of LPS, BLP, and poly I:C on IL-32 synthesis and 
release by RA FLSs
IL-32 mRNA expression was also compared in normal,
OA, and RA FLSs activated with TLR ligands (LPS, BLP,
and poly I:C). As shown in Figure 3a, amounts of IL-32
transcripts were higher in stimulated FLSs isolated from
RA patients compared with OA and normal FLSs.
IL-32 β, γ, and δ mRNA expression was induced in RA
FLSs in response to either BLP or poly I:C after 4 h (Fig-
ure 3b), with a lower induction after a 24-h stimulation
(Figure 3c). LPS induced only IL-32β and δ isoforms (Fig-
ure 3b). An increase (fivefold) of IL-32α mRNA was
d e t e c t e d  o n l y  i n  p o l y  I : C - a c t i v a t e d  F L S  ( F i g u r e  3 b ,  c ) .
Immunostaining and ELISA demonstrated the presence
and release of mature IL-32 protein in FLSs stimulated by
LPS, BLP, and poly I:C (Figure 3d/c,/d,/e and 3e). IL-32α
was also expressed intracellularly in response to poly I:C
(Figure 3f) but not released (data not shown).
The inflammatory environment of the synovial cavity is
complex in RA, because most of cytokines are present in
the synovial cavity and can interact with each other. We
therefore investigated whether a combination of TNF-α
(10 ng/ml) and IFN-γ (0.1 ng/ml) could modulate levels
of IL-32 mRNA expression by FLSs, because FLS are
exposed to both cytokines in the synovium during RA.Alsaleh et al. Arthritis Research & Therapy 2010, 12:R135
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Concomitant stimulation of FLS with IFN-γ and TNF-α
resulted in a strong induction of IL-32 mRNA expression
as compared with stimulation with only one of these
cytokines. This synergistic effect was observed in IL-32
mRNA 4 h and 24 h after activation with TNF-α and IFN-
γ (Figure 4a) but was not observed at the protein level by
using ELISA (Figure 4b). However, a concordant effect on
mRNA and protein stimulation with both cytokines was
demonstrated for the α isoform of IL-32 (Figure 4c, d).
We also studied the effect of a concomitant stimulation
of IFN-γ (0.1 ng/ml) and either BLP , LPS, or poly I:C.
Stimulation of FLS with IFN-γ (0.1 ng/ml) and either of
these PAMPs strongly induced the transcript levels of IL-
32 mRNA as compared with FLSs activated with the same
amount of IFN-γ alone (Figure 5a). This effect was
observed after 4 h of stimulation but not after 24 h. A
synergistic effect on IL-32 release was observed after acti-
vation with IFN-γ and either LPS, BLP, or poly I:C (Figure
5b). Moreover, LPS, BLP, and poly I:C also exert a syner-
gistic effect on IL-32α mRNA synthesis and IL-32α intra-
cellular expression, when combined with IFN-γ (Figure
5c, d).
Role of IRF-1 in the synergistic induction of IL-32
We subsequently analyzed the mechanisms responsible
for the synergistic effect of PAMPs or TNF-α on IFN-γ
related IL-32 induction. Previous studies showed that
nuclear concentrations of IFN regulatory factor-1 (IRF-1)
were found to increase after stimulation with IFN-γ and
TNF-α compared with stimulation with individual cytok-
ines [24,25]. We therefore evaluated IRF-1 mRNA expres-
sion in RA FLSs, stimulated with either TNF-α or IFN-γ
alone or in combination. Stimulation with IFN-γ induced
Figure 1 Effect of IFN-γ (0.1 ng/ml) on IL-32 mRNA expression and IL-32 release by rheumatoid arthritis (RA) fibroblast-like synoviocytes 
(FLSs). (a) Dose-dependent effect of IFN-γ (0.01, 0.1, and 1 ng/ml) on IL-32 mRNA expression by RA FLSs activated for 4 h. IL-32 mRNA expression in 
RA, OA, and normal FLSs activated for 4 h with IFN-γ (0.1 ng/ml). (b) IL-32 α, β, γ, and δ mRNA levels were determined by using quantitative RT-PCR in 
FLSs activated with IFN-γ for 4 h; and (c) 24 h. (d) Confocal analysis of IL-32 expression in FLSs activated for 16 h with IFN-γ (c) or medium (a, b). (e) IL-
32 release in culture supernatants was determined with ELISA after stimulation with IFN-γ or medium (c) for 24 and 48 h. (f) Intracellular IL-32α expres-
sion was determined with a cell-based ELISA in FLSs activated for 16 and 24 h with IFN-γ or medium (c). Data are expressed as the mean ± SD of three 
experiments (triplicates) on samples from four different patients with RA. *P < 0.01.Alsaleh et al. Arthritis Research & Therapy 2010, 12:R135
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IRF-1 mRNA expression in activated RA FLSs, and con-
comitant stimulation of FLSs with IFN-γ and TNF-α
resulted in a stronger increase of IRF-1 mRNA expression
(Figure 6a). These results indicate that a simultaneous
stimulation with TNF-α has a synergistic effect on IFN-γ-
induced IRF-1 transcription in FLSs.
To determine whether IRF-1 is necessary for IL-32
mRNA synthesis by stimulated FLSs, cells were trans-
fected with siRNA targeting IRF-1 or control siRNA for
48 h and then stimulated with TNF-α and IFN-γ alone or
in combination. Transfection with siRNAs did not affect
cell viability, assessed by the MTT test. We first con-
firmed that transfection of siRNA targeting IRF-1
impaired endogenous IRF-1mRNA expression, as com-
pared with IRF-1 expression in cells transfected with a
nontargeting, control siRNA (Figure 6b). Inhibition of
IRF-1 significantly reduced IL-32 mRNA expression after
TNF-α, IFN-γ, and TNF-α + IFN-γ stimulation of FLSs
(Figure 6c). This role of IRF-1 in the synergy between
TNF-α and IFN-γ was specific to IL-32, because the
release of IL-6, another proinflammatory cytokine, was
not modified after inhibition of IRF-1 (Figure 6d). Stimu-
lation with either LPS, BLP or poly I:C did not induce
IRF-1 mRNA expression but IRF-3 mRNA (Figure 6e),
and no synergic effect either on IRF-1 or IRF-3 mRNA
expression was observed when FLSs were concomitantly
stimulated with IFN-γ and LPS, BLP, or poly I:C (Figure
6e). Likewise, by using IRF-1 siRNA, the synergy between
LPS and IFN-γ was not modified (Figure 6f), converse to
that observed after stimulation with IFN-γ and TNF-α.
Thus, these results indicate that IRF-1 is involved in the
synergistic effect of TNF-α and IFN-γ on IL-32 mRNA
Figure 2 Effect of TNF-α (10 ng/ml) on IL-32 mRNA expression and IL-32 release by RA fibroblast-like synoviocytes (FLSs). (a) Dose-depen-
dent effect of TNF-α (1, 5, 10, and 20 ng/ml) on IL-32 mRNA expression by RA FLSs activated for 4 h. IL-32 mRNA expression in RA, OA, and normal FLSs 
activated for 4 h with TNF-α (10 ng/ml). (b) IL-32 α, β, γ, and δ mRNA levels were determined by using quantitative RT-PCR in FLSs activated with TNF-
α for 4 h and (c) 24 h. (d) Confocal analysis of IL-32 expression in FLSs activated for 16 h with TNF-α (c) or medium (a, b). (e) IL-32 release was deter-
mined after stimulation for 24 and 48 h with TNF-α or medium (c) with ELISA.(f) Intracellular IL-32α expression was determined with a cell-based ELISA 
in FLSs activated for 16 and 24 h with TNF-α or medium (c). Data are expressed as the mean ± SD of three experiments (triplicates) on samples from 
four different patients with RA. *P < 0.01.Alsaleh et al. Arthritis Research & Therapy 2010, 12:R135
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expression by activated FLSs, but IRF-1 and IRF-3 are not
implicated in the synergy for the induction of IL-32
observed between IFN-γ and the PAMPs studied.
Discussion
The synovial expression of IL-32, a potent proinflamma-
tory cytokine, is increased in RA and correlated with dis-
ease activity [10]. A recent study demonstrated that
resident cells of joints, FLSs, which secrete proinflamma-
tory cytokines such as IL-6 and IL-8 but not TNF-α or IL-
1β, secrete high levels of IL-32 [26,27]. The expression of
cytokines by FLSs is regulated, at least partly, by innate
immunity. However, little is known regarding the innate-
immune-related regulation of IL-32 by FLSs. We demon-
strated that proinflammatory cytokines involved in the
pathogenesis of RA, as well as stimulation of various TLR
receptors, result in the expression of IL-32 by FLSs, key
target and resident cells of RA. Moreover, a synergistic
interaction between IFN-γ and PAMPs for IL-32 induc-
tion was observed. We demonstrated that synergy
between TNF-α and IFN-γ was related to the induction of
IRF-1.
We first confirmed studies from Mun et al. [26] and
Shoda et al. [27], demonstrating that activation of FLSs
with TNF-α caused IL-32 synthesis and release. The abil-
ity of IFN-γ to induce IL-32 production in epithelial cells
and monocytes was previously reported by Kim et al. [3].
IFN-γ is produced in RA by either by CD4+ T cells, or by
subsets of CD8+ CD40L T cells or CD4+T cells, which
express KIR2DS2 and NKG2D receptors. Immunohis-
tochemical studies have shown the reinforced expression
of Stat proteins in rheumatoid synovial tissues, which
Figure 3 Effect of TLR2, TLR3, and TLR4 ligands on IL-32 mRNA expression and IL-32 release by RA fibroblast-like synoviocytes (FLSs). (a) IL-
32 mRNA expression in RA, OA, and normal FLSs activated for 4 h with either 1 μg/ml of lipopolysaccharide LPS, or 1 μg/ml of BLP, or 10 μg/ml of poly 
I:C. (b) IL-32 α, β, γ, and δ mRNA levels were determined by using quantitative RT-PCR in FLSs activated with either 1 μg/ml of LPS, or 1 μg/ml of BLP, 
or 10 μg/ml of poly I:C for 4 h, and (c) 24 h. (d) Confocal analysis of IL-32 expression in FLSs activated for 16 h with either LPS (c), BLP (d), poly I:C (e), 
or medium (a, b). (e) IL-32 release was determined with ELISA after stimulation for 24 and 48 h with either LPS, BLP, poly I:C, or medium (c). (f) Intrac-
ellular IL-32α expression was determined with a cell-based ELISA in FLSs activated for 16 h with either LPS, BLP, poly I:C, or medium (c). Data are ex-
pressed as the mean ± SD of three experiments (triplicates) on samples from four different patients with RA. *P < 0.01.Alsaleh et al. Arthritis Research & Therapy 2010, 12:R135
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suggests the importance of the IFN-γ/JAK/Stat pathway
[28,29]. Moreover, under most conditions in RA, IFN-γ
release correlates with TNF-α production [30]. We there-
fore assessed the role of IFN-γ in IL-32 synthesis and
secretion by FLSs. Exposure to IFN-γ increased IL-32
mRNA transcription and protein release, as demon-
strated for TNF-α. In RA FLSs, IFN-γ is unlikely to func-
tion as a direct inducer of proinflammatory cytokines
s y n t h e s i s ,  s u c h  a s  t h a t  o f  T N F - α ,  I L - 6 ,  a n d  I L - 8  [ 1 7 ] .
Thus, these data suggest that IFN-γ, by means of IL-32
release, might play an important role in the amplification
of inflammatory reactions in RA.
An important issue relevant to this study is represented
by the induction of IL-32 mRNA transcription in
response to LPS, BLP, and poly I:C. This effect was partic-
ularly significant in response to BLP and poly I:C at 4 h,
with a decrease at 24 h corresponding to a kinetic differ-
ent from the one obtained with IFN-γ and TNF-α. How-
ever, this is frequently observed with certain cytokines
such as TNF-α. These findings are not concordant with
results from Netea's group [7] on activated PBMCs,
showing that TLR2 and TLR3 ligands did not induce an
increase in IL-32 release. In keeping with their results, we
also observed that LPS was a moderate inducer of IL-32
expression in RA FLSs.
IL-32 is transcribed as six alternative splice variants.
Splice variants are quite unusual for cytokines, but they
exist in other cytokines such as IL-15 and IL-1F7. The
four spliced variants are expressed in TNF-α-stimulated
RA FLSs, but their respective roles in RA pathogenesis
remain to be determined [31]. In this study, we observed
that β, γ, and δ isoforms were transcribed in FLSs acti-
vated with either TNF-α, IFN-γ, BLP, or poly I:C. The β
and δ isoforms were moderately induced by LPS.
Interestingly, we demonstrated that IL-32α mRNA is
upregulated in response to TNF-α and poly I:C and that
t h i s  v a r i a n t  i s  o n l y  c e l l  a s s o c i a t e d  i n  F L S s  a n d  n e v e r
released. This is in agreement with a study in PBMCs
showing that IL-32α expression is upregulated in
response to Mycobacterium tuberculosis and remained
Figure 4 Effect of co-stimulation of TNF-α (10 ng/ml) and IFN-γ (0.1 ng/ml) on IL-32 mRNA expression and IL-32 release by RA fibroblast-
like synoviocytes (FLSs). (a) FLSs were incubated simultaneously with IFN-γ and TNF-α, and IL-32 mRNA levels were determined after activation for 
4 h and 24 h by using quantitative RT-PCR. (b) IL-32 release was determined with ELISA in culture supernatants. (c) IL-32α mRNA levels were deter-
mined by using quantitative RT-PCR in FLSs activated with either IFN-γ and TNF-α or medium (c). (d) Intracellular IL-32α expression was determined 
in IFN-γ + TNF-α- or medium-activated (c) FLSs. Data are expressed as the mean ± SD of three experiments (triplicates) on samples from four different 
patients with RA. *P < 0.01; **P < 0.001.Alsaleh et al. Arthritis Research & Therapy 2010, 12:R135
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cell associated [7]. This effect might depend on cell-type,
because IL-32α can be released by some epithelial cells
lines in response to IFN-γ, TNF-α and IL-1β [9].
IFN-γ and TNF-α are cytokines characterized by com-
plex reciprocal effects. They synergize to increase colla-
gen synthesis by dermal fibroblasts or
glycosaminoglycans synthesis by lung fibroblasts, and
they are tightly involved in the inflammatory response
during septic shock [32,33]. An important result is that
IRF-1 is required for the synthesis of IL-32 by TNF-α. Its
role in IFN-γ signaling is well known, but not in TNF-α
signaling. W e also showed that this effect is specific, as
IRF-1 does not play any role in IL-6 synthesis. Of note in
the present study, TNF-α exerts a synergistic effect on
IFN-γ- induced IL-32 mRNA, which is related to IRF-1
upregulation. The expression of IL-32 mRNA was consid-
erably reduced (70%) after inhibition of IRF-1 in FLSs
activated with a combination of TNF-α and INF-γ.
Unexpectedly, release of IL-32 protein, was not
increased after TNF-α and IFN-γ stimulation, but the
intracellular expression of the IL-32α was upregulated.
Similar results were obtained in epithelial cells, in which a
combination of TNF-α and INF-γ increased IL-32α
expression [9]. Knowledge of the role of intracellular IL-
32 is still limited, but IL-32α may play a role as a cytoplas-
mic protein. Recently it was demonstrated that IL-32α
acts synergistically with NOD-specific peptidoglycans for
the release of inflammatory cytokines [5].
Concomitant stimulation with IFN-γ and other TLR
ligands also increased IL-32 mRNA expression and pro-
tein release, but the mechanism involved in these syner-
gies remains to be identified. We demonstrated that they
are not related to IRF-1, converse to the synergy between
IFN-γ and TNF-α. Thus, these concomitant stimulations
did not upregulate IRF-1, and IRF-1 silencing did not
inhibit the synergy between IFN-γ and PAMPs for IL-32
induction. A hallmark of tissue injury is the turnover of
extracellular matrix components, which can subsequently
act as DAMPs. Increased accumulation of fragmented
hyaluronan was noticed in several autoimmune diseases.
Figure 5 Effect of co-stimulation of IFN-γ (0.1 ng/ml) with either lipopolysaccharide (LPS; 1 μg/ml), BLP (1 μg/ml), or poly I:C (10 μg/ml) on 
IL-32 mRNA expression and IL-32 release by RA fibroblast-like synoviocytes (FLSs). (a) FLSs were incubated simultaneously with IFN-γ and either 
LPS, BLP, or poly I:C. IL-32 mRNA levels were determined after activation by using quantitative RT-PCR, and IL-32 release was determined with ELISA 
(b). (c) IL-32α mRNA levels were determined with quantitative RT-PCR. (d) Intracellular IL-32α expression was evaluated in FLSs with a cell-based ELISA. 
Data are expressed as the mean ± SD of three experiments (triplicates) on samples from four different patients with RA. *P < 0.01; **P < 0.001.Alsaleh et al. Arthritis Research & Therapy 2010, 12:R135
http://arthritis-research.com/content/12/4/R135
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Hyaluronan fragments signal through TLR2 and TLR4 in
macrophages, and tenascin-C activates TLR4 in mac-
rophages and FLSs [34,35]. Moreover, RNA release from
necrotic cells acts as and endogenous TLR3 ligand for the
stimulation of proinflammatory cytokines release [36].
Therefore, our data raise the possibility that triggers,
including bacterial components, of endogenous ligands
may promote IL-32 synthesis and release by activating
TLR pathways.
Conclusions
IL-32 is known to activate the p38MAPK and the NF-κB
signal-transduction pathways and to induce the expres-
sion of other proinflammatory cytokines, such as TNF-α,
IL-1β, and IL-18, partly by amplifying the signals induced
by NOD2 [5,7]. Because these cytokines are never
released by activated FLSs, the present data suggest that
FLSs may play an important role in the amplification of
inflammatory reactions in RA, by expressing IL-32,
which in turn induces the expression of TNF-α, IL-1, or
IL-18 by macrophages or dendritic cells, bridging innate
and adaptive immunity. IL-32 might therefore represent a
relevant therapeutic target in RA.
Abbreviations
DAMPs: damage-associated molecular patterns; FLS: fibroblast-like synovio-
cyte; IRF-1: IFN regular factor; LPS: lipopolysaccharide; PAMPs: pathogen-associ-
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pattern-recognition receptors; RA: rheumatoid arthritis.
Figure 6 Effect of co-stimulation of either TLR ligands or TNF-α (10 ng/ml) and IFN-γ (0.1 ng/ml) on IRF-1 and IRF-3 mRNA expression. (a) 
Fibroblast-like synoviocytes (FLSs) were incubated simultaneously with IFN-γ and TNF-α, and IFN regular factor (IRF-1) mRNA expression was assessed 
after activation (4 and 24 h) by using quantitative RT-PCR. (b, c) Rheumatoid arthritis (RA) FLSs were transfected with IRF-1 antisense molecules or with 
a negative control (Control). Concomitant activation with IFN-γ and TNF-α of transfected RA FLSs was performed 24 h after transfection, for 4 h. IRF-1 
(b) IL-32 (c) expression was determined with quantitative RT-PCR. (d) IL-6 release was determined with ELISA after co-stimulation with IFN-γ and TNF-
α. (e) FLSs were incubated with IFN-γ or with IFN-γ and either LPS (1 μg/ml), BLP (1 μg/ml), or poly I:C (10 μg/ml) for 4 h. IFN regular factor (IRF-1) and 
IRF-3 mRNA expression was determined by using quantitative RT-PCR. (f) RA FLSs were transfected with IRF-1 antisense molecules or with a negative 
control (Control). Concomitant activation with IFN-γ and LPS of transfected RA FLSs was performed 24 h after transfection, for 4 h. IL-32 expression 
was determined with quantitative RT-PCR. Data are expressed as the mean ± SD of three experiments (triplicates) on samples from four different pa-
tients with RA. **P < 0.001.Alsaleh et al. Arthritis Research & Therapy 2010, 12:R135
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